View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 19, 2020

Coronavirus company news summary – Moderna signs access deals with Israel for Covid-19 vaccine – Russian institutes begin clinical trials of Covid-19 vaccine candidate

By Allie Nawrat

19 June 2020 

Russian Health Ministry has announced that clinical trials of a vaccine to treat Covid-19 have begun in the country. According to statement issued by the ministry, the two kinds of vaccine (liquid and powder) developed by Moscow-based Gamaleya research institute will be tested on two groups of 38 people each. These two groups include military and civilians who have been chosen to test the safety and efficacy of the vaccine.

The Government of Israel has signed an agreement with US-based Moderna for the purchase of its potential Covid-19 vaccine in the future. This deal was announced by Israeli Prime Minister Benjamin Netanyahu, but financial details were not divulged. Last week, the US biotech company confirmed its plans to begin a Phase III trial of its vaccine on 30,000 volunteers in July.

Central Drug Research Institute (CDRI), a constituent lab of India-based Council of Scientific and Industrial Research (CSIR), has secured approval for carrying out Phase III trial for the use of Umifenovir to treat Covid-19. In this randomised, double-blind, placebo-controlled trial, CDRI will test the efficacy, safety and tolerability of  Umifenovir. Umifenovir is a drug primarily used to treat influenza; available in China and Russia, the drug rose to prominence given its potential against Covid-19.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology